TY - JOUR
T1 - Platelet activation during haemodialysis
T2 - Comparison of cuprammonium rayon and polysulfone membranes
AU - Thijs, Abel
AU - Grooteman, Muriel P.C.
AU - Zweegman, Sonja
AU - Nubé, Menso J.
AU - Huijgens, Peter C.
AU - Stehouwer, Coen D.A.
PY - 2008/1/1
Y1 - 2008/1/1
N2 - Background/Aim: Haemodialysis-treated patients are at a high risk of developing cardiovascular disease. Part of this risk may be attributable to the type of the dialysis membrane used. We evaluated whether different dialysis membranes differ with respect to platelet activation. Methods: In a randomized crossover trial, the platelet activation was measured in 14 patients treated with two different dialyzers (cuprammonium rayon membrane and polysulfone membrane). We compared the platelet activation over the dialyzer and between dialyzers after several weeks of dialysis. Results: There were no differences between the two dialyzers in platelet activation over the dialyzer. After 2 weeks, however, the expression of CD62P, CD63, and PAC-1 was statistically significantly lower after cuprammonium membrane treatment than after polysulfone membrane treatment (mean fluorescence intensity in arbitrary units 8.0 vs. 11.1, 2.64 vs. 4.01, and 5.61 vs. 9.74, respectively). Conclusion: Dialysis with a polysulfone membrane seems to lead to more platelet activation than dialysis with a cuprammonium membrane.
AB - Background/Aim: Haemodialysis-treated patients are at a high risk of developing cardiovascular disease. Part of this risk may be attributable to the type of the dialysis membrane used. We evaluated whether different dialysis membranes differ with respect to platelet activation. Methods: In a randomized crossover trial, the platelet activation was measured in 14 patients treated with two different dialyzers (cuprammonium rayon membrane and polysulfone membrane). We compared the platelet activation over the dialyzer and between dialyzers after several weeks of dialysis. Results: There were no differences between the two dialyzers in platelet activation over the dialyzer. After 2 weeks, however, the expression of CD62P, CD63, and PAC-1 was statistically significantly lower after cuprammonium membrane treatment than after polysulfone membrane treatment (mean fluorescence intensity in arbitrary units 8.0 vs. 11.1, 2.64 vs. 4.01, and 5.61 vs. 9.74, respectively). Conclusion: Dialysis with a polysulfone membrane seems to lead to more platelet activation than dialysis with a cuprammonium membrane.
KW - Biocompatibility, dialysis membranes
KW - Cuprammonium rayon vs. polysulfone membranes
KW - Platelet activation, haemodialysis
UR - http://www.scopus.com/inward/record.url?scp=38849159503&partnerID=8YFLogxK
U2 - https://doi.org/10.1159/000108628
DO - https://doi.org/10.1159/000108628
M3 - Article
C2 - 17890860
SN - 0253-5068
VL - 25
SP - 389
EP - 394
JO - Blood purification
JF - Blood purification
IS - 5-6
ER -